Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 9/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053041 | 0.81 | MEN1 (0.42) | ALDH1A1F10MEN1KMT2A | |
| SCHEMBL6893668 | 0.78 | ALDH1A1 (0.35) | ALDH1A1MAPTCYP3A4CYP2C19F10 | |
| Hydrochloric Acid SCHEMBL7051531 | 0.74 | F10 (0.39) | F10 | |
| SCHEMBL7054303 | 0.73 | STS (0.41) | F10 | |
| SCHEMBL6896840 | 0.71 | PKM (0.37) | MAPT | |
| SCHEMBL7118181 | 0.70 | F10 (0.46) | MAPTF10 | |
| Hydrochloric Acid SCHEMBL7050611 | 0.69 | F10 (0.41) | F10 | |
| SCHEMBL7050346 | 0.68 | F10 (0.56) | F10 | |
| SCHEMBL5741347 | 0.68 | STS (0.40) | MAPTF10 | |
| Hydrochloric Acid SCHEMBL7048116 | 0.68 | F10 (0.55) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680312-B2 | FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6403595-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1054005-A1 | SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | F12, F11, F2 | ALDH1A1 2304/4885MAPT 4851/4885CYP3A4 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.